In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Gilead gets global rights to Tibotec's TMC278

Executive Summary

Gilead Sciences has received exclusive worldwide rights (excluding Japan) to Tibotec Pharmaceuticals' (a Johnson & Johnson division that works on infectious disease therapeutics) TMC278 (rilpivirine), an investigational non-nucleoside reverse transcriptase inhibitor. Gilead will combine TMC278 with its Truvada (emtricitabine/tenofovir disoproxil) to create a once-daily fixed-dose antiretroviral therapy for HIV-1 infected adults.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • R&D and Marketing (Licensing)

Related Companies